<DOC>
	<DOC>NCT02422940</DOC>
	<brief_summary>This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER twice daily tablets when administered for at least 12 months to subjects with chronic post-ischemic stroke walking deficits who have completed the controlled, double-blind Study DALF-PS-1016.</brief_summary>
	<brief_title>An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Key Completion of the DALFPS1016 study Providing informed consent to continue into the DALFPS1029 longterm extension study Sufficient ambulatory ability to independently complete the Two Minute Walk Test (2MinWT) and 10 Meter Walk Test (10MWT) at the time of enrollment into the extension study Key Seizures, new onset strokes (or other significant neurological event precluding longterm continuation) occurring during the antecedent DALFPS1016 study Calculated creatinine clearance of â‰¤ 50 mL/minute at the time of enrollment into the longterm extension study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>